Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Abstract Aims/hypothesis We aimed to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus decreases the risk of new-onset adverse cardiovascular events (CVEs) and mortality rate compared with other glucose-lowering drugs in a real setting at a population level
The agency did not note any concerns about the clinical data package or safety of dasiglucagon, according to Zealand
Musdal et al
PLOS Biology provides an Open Access platform to showcase your best research and commentary across all areas of biological science
US$ 27.85
US$ 21.28
US$ 27.96
